×

Biomarkers for prediction of major adverse cardiac events and uses thereof

  • US 8,501,420 B2
  • Filed: 08/30/2010
  • Issued: 08/06/2013
  • Est. Priority Date: 08/31/2009
  • Status: Expired due to Fees
First Claim
Patent Images

1. A method of determining risk of experiencing a major adverse cardiac event MACE, in a patient, within one year from presentation of at least one symptom of ACS acute coronary syndrome comprising the step of:

  • assessing the level of BNP B-type natriuretic peptide in a test sample from said patient, wherein a BNP level less than or equal to approximately 150 pg/mL indicates that the level of PlGF placental growth factor in said test sample must be assessed and a BNP level greater than approximately 150 pg/mL indicates that the eGRF of said patient must be assessed, wherein if said PlGF level must be assessed, a PlGF level less than or equal to approximately 19.5 pg/mL indicates that the level of BNP in said test sample must be reassessed, wherein if said level of BNP must be reassessed, a BNP level less than or equal to approximately 65 pg/mL indicates said patient has a low risk of experiencing a major adverse cardiac event within one year from presentation of at least one symptom of ACS and a BNP level greater than approximately 65 pg/mL indicates said patient has a moderate risk of experiencing a major adverse cardiac event within one year from presentation of at least one symptom of ACS, and wherein if eGFR must be assessed, an eGFR level greater than approximately 68 mL/min/1.73 m2 indicates said patient has a moderate risk of experiencing a major adverse cardiac event within one year from presentation of at least one symptom of ACS and an eGRF level less than or equal to approximately 68 mL/min/1.73 m2 indicates said patient has a high risk of experiencing a major adverse cardiac event within one year from presentation of at least one symptom of ACS.

View all claims
  • 1 Assignment
Timeline View
Assignment View
    ×
    ×